Premium
Menaquinone‐7 Supplementation Improves Lipid Profile in Obese African‐American Children: A Randomized Controlled Trial
Author(s) -
Pollock Norman K,
Nguyen Joshua,
Fain Mary Ellen,
Gower Barbara A.,
Bassali Reda,
Davis Catherine L
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.423.6
Subject(s) - dyslipidemia , medicine , cholesterol , endocrinology , matrix gla protein , triglyceride , lipid profile , population , blood lipids , obesity , calcium , hyperphosphatemia , environmental health
The childhood obesity surge has led to a larger population of children with dyslipidemia. Without intervention, dyslipidemia is likely to become atherosclerotic cardiovascular disease in adulthood. Menaquinones, also known as vitamin K 2, have been recently focused as a pivotal nutrient in improvement in lipid related parameters, possibly via increased carboxylation of matrix Gla‐protein (MGP). Therefore, this study investigated the dose‐response effect of menaquinone‐7 (MK‐7) supplementation on lipid profile and the inactive form of MGP (dephospho‐uncarboxylated MGP, dp‐ucMGP) in obese African‐American (AA) children. Associations between the changes in dp‐ucMGP and the changes in lipid related parameters were also determined. Fifteen obese AA children (mean age, 12.3 ± 2.9 years; mean BMI percentile, 98.8 ± 1.0; 60% female) were randomly allocated to either the control group receiving placebo or the low‐dose (45‐μg/d) or high‐dose group (90‐μg/d) receiving MK‐7 supplementation for 8 weeks. At baseline and posttest, fasting blood samples were collected for assessment of serum levels of triglycerides, total cholesterol, HDL‐cholesterol, non‐HDL‐cholesterol and LDL‐cholesterol, and plasma levels of dp‐ucMGP. After 8 weeks, dp‐ucMGP decreased significantly and dose‐dependently in the 45‐μg and 90‐μg MK‐7 supplementation groups by 8% and 22%, respectively ( P =0.02). A dose‐response benefit of MK‐7 supplementation was also observed for triglycerides, total cholesterol, non‐HDL‐cholesterol, and LDL‐cholesterol as indicated by significant downward trends (all P < 0.05). There was no dose‐response effect of MK‐7 on HDL‐cholesterol. Pearson's bivariate analyses revealed that changes in triglycerides ( r = 0.69) and non‐HDL cholesterol ( r = 0.65) were associated with changes in dp‐ucMGP (both P < 0.04). After 8‐weeks, MK‐7 supplementation demonstrated dose‐response benefits on lipid profile in obese children. Our study provides the rationale that larger intervention trials are needed to determine whether vitamin K 2 supplementation slows atherosclerosis development by increasing MGP carboxylation. Support or Funding Information This work was funded by Georgia Regents University's Intramural Grants Program.